Successful recent preclinical studies of TME targeting ADCs
| Target | TME component | ADC | Payload | Tumour types | Translation to clinic |
|---|---|---|---|---|---|
| LRRC15 | CAF | ABBV-085 | MMAF | NSCLC, osteosarcoma, breast cancer, GBM | Phase I trial in sarcoma and other advanced solid tumours (published 2021) [113] |
| FAPα | CAF | OMTX705 (+ ICI) | TAM470 (MTI) | NSCLC, TNBC, ovarian, pancreatic | Pending |
| TEM8 | Stroma | m825-MMAE | MMAE | CRC, breast, lung, ovarian, pancreatic | Pending |
| TF | Stroma | TF antibody-MMAE | MMAE | pancreatic | Phase II trial (TV) in refactaory cervical cancer—positive (published 2021) [127] |
| EphA3 | Stroma | IIIA4-USAN | USAN | GBM | Pending |
CAF: cancer associated fibroblast; Eph: erythropoietin-producing hepatocellular carcinoma; FAPα: fibroblast activating protein α; LRRC15: leucine-rich repeat containing 15; MTI: microtubule inhibitor; TEM8: tumour endothelial marker 8; TF: tissue factor; TV: tisotumab vedotin; USAN: maytansine; +: plus